[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.145.218.90. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
January 1990

MK-927: A Topical Carbonic Anhydrase InhibitorDose Response and Duration of Action

Author Affiliations

From the Departments of Ophthalmology, Eye and Ear Infirmary, University of Illinois at Chicago (Drs Higginbotham, Batenhorst, and Wilensky), and Washington University School of Medicine, St Louis, Mo (Dr Kass); and Merck Sharp & Dohme Research Laboratories, Clinical Research and Biostatistics, West Point, Pa (Dr Lippa and Ms Panebianco).

Arch Ophthalmol. 1990;108(1):65-68. doi:10.1001/archopht.1990.01070030071031
Abstract

• The dose response to a single topical administration of the carbonic anhydrase inhibitor MK-927 was investigated in 24 patients with primary open angle glaucoma or ocular hypertension. Three concentrations of MK-927 (2%, 1%, and 0.5%) and placebo were administered in a two-center, double-masked, randomized, placebo-controlled, four-period crossover study. MK-927 at the 0.5% concentration appeared to be minimally effective in reducing intraocular pressure. A single topical dose of 1% MK-927 resulted in a significantly greater percent reduction in intraocular pressure for up to 6 hours when compared with treatment with placebo. Similarly, a single dose of 2% MK-927 significantly lowered intraocular pressure for 8 hours compared with treatment with placebo. The pressure reduction from baseline measured 23.7% and 11.3% at 8 hours after instillation of a single drop of 2% MK-927. The medication was well tolerated and appeared to lower intraocular pressure in a dose-dependent fashion.

×